Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Abstract Background Overexpression of HER2 plays an important role in cancer progression and is the target of multiple therapies in HER2‐positive breast cancer. Recent studies have also highlighted the presence of activating mutations in HER2, and HER3 that are predicted to enhance HER2 downstream p...

Full description

Bibliographic Details
Main Authors: Page E. Blas, Esther San Roman Rodriguez, Heather L. Williams, Maren K. Levin, Joshua S. K. Bell, Mariaelena Pierobon, Alexander S. Barrett, Emanuel F. Petricoin, Joyce A. O'Shaughnessy
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Cancer Reports
Subjects:
cancer biology
exceptional responder
HER2/HER3 co‐mutations
metastatic breast cancer
Online Access:https://doi.org/10.1002/cnr2.1954

Internet

https://doi.org/10.1002/cnr2.1954

Similar Items